Trial
NCT00701714
Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Sandoz
Collaborators
—
Condition
Anemia
Intervention
HX575 recombinant human erythropoietin alfa
Why stopped
investigation of adverse events
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-05